prikaz prve stranice dokumenta Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Pregledni rad
Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
Rheumatology International, 44 (2024), 5; 749-755. https://doi.org/10.1007/s00296-023-05531-y
Zekić, Tatjana; Belančić, Andrej

Citirajte ovaj rad

Zekić, T. i Belančić, A. (2024). Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic. Rheumatology International, 44. (5), 749-755. doi: 10.1007/s00296-023-05531-y

Zekić, Tatjana i Andrej Belančić. "Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic." Rheumatology International, vol. 44, br. 5, 2024, str. 749-755. https://doi.org/10.1007/s00296-023-05531-y

Zekić, Tatjana i Andrej Belančić. "Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic." Rheumatology International 44, br. 5 (2024): 749-755. https://doi.org/10.1007/s00296-023-05531-y

Zekić, T. i Belančić, A. (2024) 'Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic', Rheumatology International, 44(5), str. 749-755. doi: 10.1007/s00296-023-05531-y

Zekić T, Belančić A. Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic. Rheumatology International [Internet]. 23.02.2024. [pristupljeno 24.12.2024.];44(5):749-755. doi: 10.1007/s00296-023-05531-y

T. Zekić i A. Belančić, "Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic", Rheumatology International, vol. 44, br. 5, str. 749-755, Veljača 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:102616. [Citirano: 24.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:102616
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
AutorTatjana Zekić
AutorAndrej Belančić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Thrombosis is one of the many signs of antiphospholipid syndrome (APS) and COVID- 19 infection. Although the mechanisms contributing to thrombosis in APS and COVID- 19 are relatively similar, this remains an open subject. Even now (when the COVID-19 pandemic has subsided), there is no conclusive solution to APS and COVID-19 cooccurrence. The presence of newly generated antiphospholipid antibodies (aPLs) in COVID-19 infection may or may not be connected to the diagnosis of APS. The prevalence of aPLs is substantial in severe COVID-19 but not related to thrombosis or a worse outcome. Adequate monitoring of antibody positivity over time is recommended for APL diagnosis. On the other hand, thrombosis and thrombocytopenia can rarely occur with vaccination with mRNA vaccines. Some studies have shown that COVID-19 immunization is well tolerated among APS patients who are triple-positive for aPL, which may comfort patients and referring physicians and lessen hesitation in unvaccinated APS/aPL-positive patients. In this narrative review we will give an overview of the interaction between aPL-APS-COVID-19- thrombosis and related diagnostic insights learned during the pandemic.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaRheumatology International
Brojčani podacivol. 44, br. 5, str. 749-755
e-ISSN1437-160X
DOIhttps://doi.org/10.1007/s00296-023-05531-y
URN:NBNurn:nbn:hr:184:102616
Datum objave publikacije2024-02-23
URL dokumentahttps://link.springer.com/10.1007/s00296-023-05531-y
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-12-09 12:52:44